[go: up one dir, main page]

BRPI0921858A2 - combinações antitumorais contendo os anticorpos reconhecendo especificamente cd38 e citarabina - Google Patents

combinações antitumorais contendo os anticorpos reconhecendo especificamente cd38 e citarabina

Info

Publication number
BRPI0921858A2
BRPI0921858A2 BRPI0921858A BRPI0921858A BRPI0921858A2 BR PI0921858 A2 BRPI0921858 A2 BR PI0921858A2 BR PI0921858 A BRPI0921858 A BR PI0921858A BR PI0921858 A BRPI0921858 A BR PI0921858A BR PI0921858 A2 BRPI0921858 A2 BR PI0921858A2
Authority
BR
Brazil
Prior art keywords
cytarabine
antibodies specifically
specifically recognizing
containing antibodies
combinations containing
Prior art date
Application number
BRPI0921858A
Other languages
English (en)
Inventor
Lejeune Pascale
Vrignaud Patricia
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921858(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI0921858A2 publication Critical patent/BRPI0921858A2/pt
Publication of BRPI0921858B1 publication Critical patent/BRPI0921858B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
BRPI0921858-0A 2008-11-28 2009-11-27 Combinação farmacêutica sinérgica compreendendo anticorpos que reconhecem, especificamente, cd38 e citarabina, e usos dos mesmos BRPI0921858B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08291118.1 2008-11-28
EP08291118A EP2191842A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
PCT/IB2009/055391 WO2010061359A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine

Publications (2)

Publication Number Publication Date
BRPI0921858A2 true BRPI0921858A2 (pt) 2018-10-09
BRPI0921858B1 BRPI0921858B1 (pt) 2022-11-16

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921858-0A BRPI0921858B1 (pt) 2008-11-28 2009-11-27 Combinação farmacêutica sinérgica compreendendo anticorpos que reconhecem, especificamente, cd38 e citarabina, e usos dos mesmos

Country Status (39)

Country Link
US (1) US20120093806A1 (pt)
EP (2) EP2191842A1 (pt)
JP (2) JP2012510463A (pt)
KR (1) KR101715958B1 (pt)
CN (2) CN107096022A (pt)
AR (1) AR073425A1 (pt)
AU (1) AU2009321251B2 (pt)
BR (1) BRPI0921858B1 (pt)
CA (1) CA2745005C (pt)
CL (1) CL2011001232A1 (pt)
CO (1) CO6440556A2 (pt)
CR (1) CR20110282A (pt)
DK (1) DK2370096T5 (pt)
EA (1) EA027070B1 (pt)
EC (1) ECSP11011071A (pt)
ES (1) ES2638926T3 (pt)
HN (1) HN2011001423A (pt)
HR (1) HRP20171301T1 (pt)
HU (1) HUE035910T2 (pt)
IL (2) IL213118A (pt)
LT (1) LT2370096T (pt)
MA (1) MA32899B1 (pt)
MX (1) MX344973B (pt)
NI (1) NI201100107A (pt)
NZ (1) NZ593085A (pt)
PA (1) PA8849901A1 (pt)
PE (1) PE20120205A1 (pt)
PL (1) PL2370096T3 (pt)
PT (1) PT2370096T (pt)
RS (1) RS56248B1 (pt)
SG (1) SG171821A1 (pt)
SI (1) SI2370096T1 (pt)
SM (1) SMT201700403T1 (pt)
TN (1) TN2011000242A1 (pt)
TW (1) TWI436770B (pt)
UA (1) UA104160C2 (pt)
UY (1) UY32266A (pt)
WO (1) WO2010061359A1 (pt)
ZA (1) ZA201104064B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
JP6087283B2 (ja) 2010-09-27 2017-03-01 モルフォシス・アー・ゲー 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HRP20171964T1 (hr) 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
ES2808565T3 (es) 2013-03-13 2021-03-01 Sanofi Sa Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib
WO2015066450A1 (en) * 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6707531B2 (ja) 2014-09-09 2020-06-10 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体による併用療法
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
EP3297729A4 (en) 2015-05-20 2019-04-10 Janssen Biotech, Inc. ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT-CHAINED AMYLOIDOSES AND OTHER CD38-POSITIVE HEMATOLOGICAL MALIGNITIES
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10746739B2 (en) * 2015-09-14 2020-08-18 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating RhoH
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SI3370770T1 (sl) 2015-11-03 2021-03-31 Janssen Biotech, Inc. Subkutane formulacije protiteles proti CD38 in njihove uporabe
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3703749A1 (en) 2017-10-31 2020-09-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CA3130132A1 (en) 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
BR112022010905A2 (pt) 2019-12-05 2022-09-06 Sanofi Aventis Us Llc Formulações de anticorpos anti-cd38 para administração subcutânea
KR20230142834A (ko) 2021-01-14 2023-10-11 모르포시스 아게 항-cd38 항체 및 이의 용도
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU770718B2 (en) * 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
NZ586780A (en) * 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2245065A1 (en) * 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Also Published As

Publication number Publication date
DK2370096T3 (en) 2017-07-17
CO6440556A2 (es) 2012-05-15
TW201023863A (en) 2010-07-01
MX2011005666A (es) 2011-09-30
AU2009321251A1 (en) 2010-06-03
KR101715958B1 (ko) 2017-03-14
ES2638926T3 (es) 2017-10-24
CA2745005A1 (en) 2010-06-03
IL213115A (en) 2017-08-31
HN2011001423A (es) 2014-01-13
EA027070B1 (ru) 2017-06-30
NZ593085A (en) 2012-12-21
PA8849901A1 (es) 2010-07-27
KR20110096551A (ko) 2011-08-30
TWI436770B (zh) 2014-05-11
PL2370096T3 (pl) 2017-10-31
LT2370096T (lt) 2017-09-25
MX344973B (es) 2017-01-12
US20120093806A1 (en) 2012-04-19
IL213118A (en) 2017-08-31
DK2370096T5 (en) 2017-09-18
PE20120205A1 (es) 2012-03-03
PT2370096T (pt) 2017-09-08
JP6072854B2 (ja) 2017-02-01
UY32266A (es) 2010-06-30
EP2370096A1 (en) 2011-10-05
SMT201700403T1 (it) 2017-11-15
IL213115A0 (en) 2011-07-31
TN2011000242A1 (en) 2012-12-17
HUE035910T2 (en) 2018-05-28
WO2010061359A1 (en) 2010-06-03
EA201100868A1 (ru) 2011-10-31
EP2370096B1 (en) 2017-05-31
CN107096022A (zh) 2017-08-29
MA32899B1 (fr) 2011-12-01
NI201100107A (es) 2011-09-26
AU2009321251B2 (en) 2016-06-09
CR20110282A (es) 2011-09-20
ECSP11011071A (es) 2011-07-29
UA104160C2 (uk) 2014-01-10
CA2745005C (en) 2020-08-11
ZA201104064B (en) 2012-09-26
EP2191842A1 (en) 2010-06-02
HRP20171301T1 (hr) 2017-10-20
AR073425A1 (es) 2010-11-03
CN102264386A (zh) 2011-11-30
RS56248B1 (sr) 2017-11-30
BRPI0921858B1 (pt) 2022-11-16
SG171821A1 (en) 2011-07-28
JP2015205893A (ja) 2015-11-19
CL2011001232A1 (es) 2012-02-10
IL213118A0 (en) 2011-07-31
JP2012510463A (ja) 2012-05-10
SI2370096T1 (sl) 2017-10-30

Similar Documents

Publication Publication Date Title
BRPI0921858A2 (pt) combinações antitumorais contendo os anticorpos reconhecendo especificamente cd38 e citarabina
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI1011005A2 (pt) anticorpos anti-epcam
RS57997B1 (sr) Antitumorske kombinacije koje sadrže antitela koja specifično prepoznaju cd38 i bortezomib
BRPI0921864A2 (pt) combinações antitumor contendo anticorpos que reconhecem especificamente cd38 e melfalano
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
EP2277301A4 (en) IMPROVED HEADSET
BRPI0922304A2 (pt) combinações antitumorais contendo anticorpos que especificamente reconhecem cd38 e vincristina
LT3284754T (lt) Antikūnai prieš cd38
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
EP2377932A4 (en) ANTI-Siglec-15 ANTIBODY
EP2207803A4 (en) Cd9-specific human antibodies
DK2307543T3 (da) Forbedret proteinekspressionssystem
HUE036477T2 (hu) Monoklonális anti-GT468 antitestek rák kezeléséhez
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
BRPI0909633A2 (pt) anticorpos anti-tyrp1
DK2252471T3 (da) Blyant
BRPI0810109A2 (pt) Portadora de identidade
BRPI0912769A2 (pt) anticorpos anti-pirb
FR2943224B3 (fr) Stylo cosmetique
DE112010002536A5 (de) Feder
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav
DE102009052755B8 (de) Kosmetikstift
ES1067475Y (es) Pendiente de adorno personal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25G Requested change of headquarter approved

Owner name: SANOFI (FR)